Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2472MR)

This product GTTS-WQ2472MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2472MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4163MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ7964MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ10537MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1869MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ10438MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ3446MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ2843MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW